Tag: discontinue treatment

FDA, Regulations

FDA slaps partial hold on Biogen, InnoCare MS drug

December 28, 2022

Via: Pharmaphorum

The US regulator has placed oral BTK inhibitor orelabrutinib on partial clinical hold, meaning new patients cannot be enrolled into clinical trials and patients treated with the drug for 70 days or less must discontinue treatment. Those already taking orelabrutinib […]